Keros Therapeutics (NASDAQ:KROS) Stock Rating Upgraded by Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

KROS has been the subject of several other reports. Leerink Partners lowered their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company dropped their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.50.

Keros Therapeutics Stock Performance

KROS opened at $11.15 on Friday. The company has a fifty day simple moving average of $10.62 and a 200 day simple moving average of $12.35. The firm has a market cap of $221.10 million, a price-to-earnings ratio of -3.01 and a beta of 0.99. Keros Therapeutics has a twelve month low of $9.69 and a twelve month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, analysts forecast that Keros Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director owned 10,958 shares of the company’s stock, valued at $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,425 shares of company stock valued at $89,994 in the last quarter. Insiders own 12.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KROS. Financial Management Professionals Inc. acquired a new position in Keros Therapeutics during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd grew its stake in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the period. Lazard Asset Management LLC acquired a new stake in Keros Therapeutics in the first quarter worth $129,000. Finally, New York State Common Retirement Fund increased its position in Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.